- Home
- IBRX vs EPAC Comparison
IBRX vs EPAC Comparison
Compare IBRX & EPAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- EPAC
- Stock Information
- Founded
- IBRX 2014
- EPAC 1910
- Country
- IBRX United States
- EPAC United States
- Employees
- IBRX N/A
- EPAC N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- EPAC Industrial Machinery/Components
- Sector
- IBRX Health Care
- EPAC Technology
- Exchange
- IBRX Nasdaq
- EPAC Nasdaq
- Market Cap
- IBRX 2.4B
- EPAC 2.4B
- IPO Year
- IBRX N/A
- EPAC N/A
- Fundamental
- Price
- IBRX $4.49
- EPAC $47.57
- Analyst Decision
- IBRX Buy
- EPAC
- Analyst Count
- IBRX 2
- EPAC 0
- Target Price
- IBRX $17.38
- EPAC N/A
- AVG Volume (30 Days)
- IBRX 10.4M
- EPAC 387.9K
- Earning Date
- IBRX 11-12-2024
- EPAC 12-17-2024
- Dividend Yield
- IBRX N/A
- EPAC 0.08%
- EPS Growth
- IBRX N/A
- EPAC 91.76
- EPS
- IBRX N/A
- EPAC 1.56
- Revenue
- IBRX $7,332,000.00
- EPAC $589,510,000.00
- Revenue This Year
- IBRX $1,563.18
- EPAC $7.26
- Revenue Next Year
- IBRX $1,262.20
- EPAC $6.07
- P/E Ratio
- IBRX N/A
- EPAC $31.71
- Revenue Growth
- IBRX 1218.71
- EPAC N/A
- 52 Week Low
- IBRX $3.10
- EPAC $27.06
- 52 Week High
- IBRX $10.53
- EPAC $51.91
- Technical
- Relative Strength Index (RSI)
- IBRX 46.07
- EPAC 56.10
- Support Level
- IBRX $4.57
- EPAC $43.62
- Resistance Level
- IBRX $5.08
- EPAC $51.91
- Average True Range (ATR)
- IBRX 0.54
- EPAC 1.23
- MACD
- IBRX -0.12
- EPAC 0.00
- Stochastic Oscillator
- IBRX 3.16
- EPAC 47.65
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.
About EPAC Enerpac Tool Group Corp.
Enerpac Tool Group, previously known as Actuant, provides high-precision tools, controlled-force products, and solutions for precise heavy lifting. The company operates through two segments: industrial tools and services and other. It categorizes its revenue into two parts: product sales and services, which include manpower services and rentals. Product sales is the largest contributor to the company's total revenue. Geographically, the company operates in the United States, Asia, Australia, Europe, Middle East, and other areas. The U.S. makes up the largest contribution to the company's total revenue.